Want to see DERM full AI Analyst Report?
DERM Stock Chart & Stats
$7.53
$0.18(2.91%)
At close: 4:00 PM EDT
$7.53
$0.18(2.91%)
Day’s Range― - ―
52-Week Range$4.31 - $9.56
Previous Close$6.37
Volume133.76K
Average Volume (3M)185.88K
Market Cap
$145.92M
Enterprise Value$194.55M
Total Cash (Recent Filing)$25.64M
Total Debt (Recent Filing)$25.54M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Nov 11, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding22,224,396
10 Day Avg. Volume196,852
30 Day Avg. Volume185,876
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)5.93
Price to Sales (P/S)3.05
P/FCF Ratio-15.18
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue2.85
Enterprise Value/Gross Profit4.58
Enterprise Value/Ebitda103.98
Forecast
1Y Price Target
$13.50Price Target Upside79.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$81.03M
Bulls Say, Bears Say
Bulls Say
Commercial GrowthStrong revenue and prescription growth indicate expanding demand for the company’s dermatology portfolio. Continued Amrozi adoption can improve operating leverage, strengthen physician relationships, and provide a durable base for further growth over the next several quarters.
Improving ProfitabilityA high gross margin combined with positive EBITDA and a sharply smaller GAAP loss shows meaningful progress toward a more sustainable earnings model. If commercial growth continues, the business may convert its product economics into recurring profitability and stronger internal funding capacity.
Broader Market AccessExpanded GPO access increases the addressable reimbursed population for Amrozi and can reduce barriers to physician prescribing. Improving formulary coverage may also support higher realized pricing and make the company’s commercial investment more productive over time.
Bears Say
Negative Cash FlowPersistent negative operating and free cash flow means the company has not yet converted improving sales into self-funded operations. Continued cash burn could limit investment flexibility and increase dependence on cash reserves while management works to establish durable profitability.
Unproven GAAP ProfitabilityThe company’s improving trajectory has not yet produced consistent GAAP earnings, leaving results dependent on continued revenue growth and expense discipline. Until profitability is sustained, weaker execution or slower adoption could prolong earnings pressure and constrain balance-sheet improvement.
Payer FrictionLimited high-quality coverage can slow prescription conversion, increase administrative hurdles, and restrain patient access across much of the commercial market. Further growth and ASP improvement therefore remain dependent on additional formulary wins and health-plan execution.
Journey Medical Corp News
DERM FAQ
What was Journey Medical Corp’s price range in the past 12 months?
Journey Medical Corp lowest stock price was $4.31 and its highest was $9.55 in the past 12 months.
What is Journey Medical Corp’s market cap?
Journey Medical Corp’s market cap is $145.92M.
When is Journey Medical Corp’s upcoming earnings report date?
Journey Medical Corp’s upcoming earnings report date is Nov 11, 2026 which is in 20 days.
How were Journey Medical Corp’s earnings last quarter?
Journey Medical Corp released its earnings results on Aug 12, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.022 by $0.012.
Is Journey Medical Corp overvalued?
According to Wall Street analysts Journey Medical Corp’s price is currently Undervalued.
Does Journey Medical Corp pay dividends?
Journey Medical Corp does not currently pay dividends.
What is Journey Medical Corp’s EPS estimate?
Journey Medical Corp’s EPS estimate is <0.01.
How many shares outstanding does Journey Medical Corp have?
Journey Medical Corp has 22,224,396 shares outstanding.
What happened to Journey Medical Corp’s price movement after its last earnings report?
Journey Medical Corp reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.022. Following the earnings report the stock price went up 3.421%.
Which hedge fund is a major shareholder of Journey Medical Corp?
Currently, no hedge funds are holding shares in DERM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Journey Medical Corp Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (79.28% Upside)
$13.50 (79.28% Upside)
Blogger Sentiment
Bullish
DERM Sentiment 60%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.80%
12-Months-Change
Fundamentals
Return on Equity
-20.23%
Trailing 12-Months
Asset Growth
21.19%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Journey Medical Corp
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
DERM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial momentum—notably strong top-line growth (total revenue +23% YoY), robust Amrozi prescription growth (≈20% sequential), expanding prescriber footprint (>40% increase since 2025 year-end), positive EBITDA and materially narrowed GAAP losses—while also acknowledging remaining headwinds around payer friction (only ~38% high-quality formulary coverage), some product-level softness (QBREXZA in the quarter), and timing uncertainty for international out-licensing. Management highlighted continued investments (new reps, marketing, a new product launch) to capitalize on momentum. On balance, the positive operational and financial progress substantially outweighs the noted challenges.View all DERM earnings summariesDERM Stock 12 Month Forecast
Average Price Target
$13.50
▲(79.28% Upside)
Technical Analysis
Ownership Overview
19.48% Insiders
14.17% Mutual Funds
12.04% Other Institutional Investors
51.07% Public Companies and
Individual Investors